Rethinking HRT: New Insights & Evolving Alternatives – BNN Breaking

Rethinking Hormone Replacement Therapy: New Insights and Evolving Alternatives

Once a standard treatment for menopausal symptoms, Hormone Replacement Therapy (HRT) stirred controversy in 2002 when a study by the Womens Health Initiative raised alarms about its potential risks. The study pointed towards increased chances of heart attack, stroke, thrombosis, and breast cancer, leading to a decline in its prescription. Fast forward to today, the same study has been reevaluated, suggesting that the original findings may have been misinterpreted due to methodological flaws.

US researchers, including JoAnn Manson of the Brigham and Womens Hospital at Harvard Medical School, have reanalyzed the 2002 study. They found that the mortality rate among women who underwent HRT was not significantly higher than in untreated women. In some cases, it was even lower. Today, HRT is prescribed less frequently and at lower dosages, but the conversation around HRT is far from over.

The Professional Association of Gynecologists emphasizes the importance of thorough medical examination, consultation, and individual risk assessment before recommending HRT. They advocate for the use of the lowest effective dose and regular annual reviews of the treatment. However, the choice of hormones and the question of whether they should be combined remains a matter of debate among gynecologists.

Interestingly, HRT has been observed to have some positive side effects. It is known to reduce the risk of osteoporosis and potentially lower the risk of coronary heart disease and Alzheimers disease if started before the age of 60. Nevertheless, the long-term effects of HRT continue to be studied, and women are advised to have comprehensive discussions with their gynecologists.

While HRT continues to be a topic of much debate, a new non-hormonal drug called fezolinetant offers a fresh perspective. Licensed for the treatment of vasomotor symptoms (VMS) associated with menopause, fezolinetant has shown promise in improving both frequency and severity of symptoms. Currently, it is approved by the Medicines and Healthcare Regulatory Agency (MHRA) for the treatment of moderate to severe VMS and is available on private prescription only.

Decades after the controversy surrounding HRT, the medical community continues to explore and debate the best ways to manage menopausal symptoms. As our understanding of HRT and its alternatives evolves, the importance of individual risk assessment and comprehensive consultation with healthcare providers remains paramount.

View original post here:
Rethinking HRT: New Insights & Evolving Alternatives - BNN Breaking